Open Access

Molecular genetics complexity impeding research progress in breast and ovarian cancers (Review)

  • Authors:
    • Ishita Gupta
    • Ikram Burney
    • Mansour S. Al‑Moundhri
    • Yahya Tamimi
  • View Affiliations

  • Published online on: May 29, 2017     https://doi.org/10.3892/mco.2017.1275
  • Pages: 3-14
  • Copyright: © Gupta et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast and ovarian cancer are heterogeneous diseases. While breast cancer accounts for 25% of cancers worldwide, ovarian cancer accounts for 3.5% of all cancers and it is considered to be the most lethal type of cancer among women. In Oman, breast cancer accounts for 25% and ovarian cancer for 4.5% of all cancer cases. Various risk factors, including variable biological and clinical traits, are involved in the onset of breast and ovarian cancer. Although highly developed diagnostic and therapeutic methods have paved the way for better management, targeted therapy against specific biomarkers has not yet shown any significant improvement, particularly in triple‑negative breast cancer and epithelial ovarian cancer, which are associated with high mortality rates. Thus, elucidating the mechanisms underlying the pathology of these diseases is expected to improve their prevention, prognosis and management. The aim of the present study was to provide a comprehensive review and updated information on genomics and proteomics alterations associated with cancer pathogenesis, as reported by several research groups worldwide. Furthermore, molecular research in our laboratory, aimed at identifying new pathways involved in the pathogenesis of breast and ovarian cancer using microarray and chromatin immunoprecipitation (ChIP), is discussed. Relevant candidate genes were found to be either up‑ or downregulated in a cohort of breast cancer cases. Similarly, ChIP analysis revealed that relevant candidate genes were regulated by the E2F5 transcription factor in ovarian cancer tissue. An ongoing study aims to validate these genes with a putative role as biological markers that may contribute to the development of targeted therapies for breast and ovarian cancer.
View References

Related Articles

Journal Cover

July 2017
Volume 7 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Gupta, I., Burney, I., Al‑Moundhri, M.S., & Tamimi, Y. (2017). Molecular genetics complexity impeding research progress in breast and ovarian cancers (Review). Molecular and Clinical Oncology, 7, 3-14. https://doi.org/10.3892/mco.2017.1275
MLA
Gupta, I., Burney, I., Al‑Moundhri, M. S., Tamimi, Y."Molecular genetics complexity impeding research progress in breast and ovarian cancers (Review)". Molecular and Clinical Oncology 7.1 (2017): 3-14.
Chicago
Gupta, I., Burney, I., Al‑Moundhri, M. S., Tamimi, Y."Molecular genetics complexity impeding research progress in breast and ovarian cancers (Review)". Molecular and Clinical Oncology 7, no. 1 (2017): 3-14. https://doi.org/10.3892/mco.2017.1275